Latest news

• GSK cues up regulatory filings for relapsing malaria drug

  One of the greatest challenges for patients with P vivax malaria is preventing relapses," said GSK's president of R&D Patrick Vallance. ... GSK is also developing a four-dose vaccine for malaria - RTS, S/AS01 - that has shown 31-56% protective efficacy

• Dosing of GSK's malaria vaccine due to start in 2018

  Funding has now been secured for vaccination programmes using GlaxoSmithKline's malaria vaccine RTS, S, with the people due to receive the shots in 2018. ... RTS, S, acts against Plasmodium falciparum, the most deadly malaria parasite globally and the

• Malaria vaccine is first to provide 'sustained protection'

  The vaccine is based on inactivated Plasmodium falciparum sporozoites, a key stage in the parasite's life cycle. ... Mosquirix (formerly known as RTS, S) also targets P. falciparum - the most virulent form of malaria which affects 214m people a year and

• World first as CHMP backs GSK malaria vaccine Mosquirix

  Formerly known as RTS, S/ASO1, Mosquirix (Plasmodium falciparum and hepatitis B vaccine) was assessed under EMA rules that allow it to assess the quality, safety and efficacy  of a medicine ... The CHMP and GSK's biologics unit agreed measures to

• Sharing knowledge to combat emerging threats

  GSK's work on a malaria vaccine is a good example of this. ... The company's RTS, S vaccine, filed for regulatory approval in Europe last year, is designed to protect against Plasmodium falciparum, the most dangerous of the mosquito-borne malaria